DexCom Statistics
Total Valuation
DexCom has a market cap or net worth of $22.78 billion. The enterprise value is $22.04 billion.
| Market Cap | 22.78B |
| Enterprise Value | 22.04B |
Important Dates
The last earnings date was Thursday, October 30, 2025, after market close.
| Earnings Date | Oct 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
DexCom has 390.02 million shares outstanding. The number of shares has decreased by -1.89% in one year.
| Current Share Class | 390.02M |
| Shares Outstanding | 390.02M |
| Shares Change (YoY) | -1.89% |
| Shares Change (QoQ) | -0.20% |
| Owned by Insiders (%) | 0.32% |
| Owned by Institutions (%) | 96.03% |
| Float | 387.42M |
Valuation Ratios
The trailing PE ratio is 32.51 and the forward PE ratio is 24.53. DexCom's PEG ratio is 1.07.
| PE Ratio | 32.51 |
| Forward PE | 24.53 |
| PS Ratio | 5.06 |
| Forward PS | 4.40 |
| PB Ratio | 8.36 |
| P/TBV Ratio | 8.69 |
| P/FCF Ratio | 21.46 |
| P/OCF Ratio | 15.73 |
| PEG Ratio | 1.07 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 21.56, with an EV/FCF ratio of 20.75.
| EV / Earnings | 30.58 |
| EV / Sales | 4.88 |
| EV / EBITDA | 21.56 |
| EV / EBIT | 28.34 |
| EV / FCF | 20.75 |
Financial Position
The company has a current ratio of 1.56, with a Debt / Equity ratio of 0.94.
| Current Ratio | 1.56 |
| Quick Ratio | 1.35 |
| Debt / Equity | 0.94 |
| Debt / EBITDA | 2.43 |
| Debt / FCF | 2.43 |
| Interest Coverage | 40.93 |
Financial Efficiency
Return on equity (ROE) is 30.63% and return on invested capital (ROIC) is 9.85%.
| Return on Equity (ROE) | 30.63% |
| Return on Assets (ROA) | 7.02% |
| Return on Invested Capital (ROIC) | 9.85% |
| Return on Capital Employed (ROCE) | 18.68% |
| Revenue Per Employee | $438,437 |
| Profits Per Employee | $69,971 |
| Employee Count | 10,300 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 3.06 |
Taxes
In the past 12 months, DexCom has paid $238.30 million in taxes.
| Income Tax | 238.30M |
| Effective Tax Rate | 24.85% |
Stock Price Statistics
The stock price has decreased by -21.98% in the last 52 weeks. The beta is 1.52, so DexCom's price volatility has been higher than the market average.
| Beta (5Y) | 1.52 |
| 52-Week Price Change | -21.98% |
| 50-Day Moving Average | 65.82 |
| 200-Day Moving Average | 76.27 |
| Relative Strength Index (RSI) | 39.89 |
| Average Volume (20 Days) | 8,649,099 |
Short Selling Information
The latest short interest is 11.17 million, so 2.86% of the outstanding shares have been sold short.
| Short Interest | 11.17M |
| Short Previous Month | 11.62M |
| Short % of Shares Out | 2.86% |
| Short % of Float | 2.88% |
| Short Ratio (days to cover) | 2.03 |
Income Statement
In the last 12 months, DexCom had revenue of $4.52 billion and earned $720.70 million in profits. Earnings per share was $1.80.
| Revenue | 4.52B |
| Gross Profit | 2.67B |
| Operating Income | 777.70M |
| Pretax Income | 959.00M |
| Net Income | 720.70M |
| EBITDA | 1.02B |
| EBIT | 777.70M |
| Earnings Per Share (EPS) | $1.80 |
Balance Sheet
The company has $3.32 billion in cash and $2.58 billion in debt, giving a net cash position of $746.50 million or $1.91 per share.
| Cash & Cash Equivalents | 3.32B |
| Total Debt | 2.58B |
| Net Cash | 746.50M |
| Net Cash Per Share | $1.91 |
| Equity (Book Value) | 2.73B |
| Book Value Per Share | 6.99 |
| Working Capital | 1.88B |
Cash Flow
In the last 12 months, operating cash flow was $1.45 billion and capital expenditures -$386.20 million, giving a free cash flow of $1.06 billion.
| Operating Cash Flow | 1.45B |
| Capital Expenditures | -386.20M |
| Free Cash Flow | 1.06B |
| FCF Per Share | $2.72 |
Margins
Gross margin is 59.01%, with operating and profit margins of 17.22% and 15.96%.
| Gross Margin | 59.01% |
| Operating Margin | 17.22% |
| Pretax Margin | 21.24% |
| Profit Margin | 15.96% |
| EBITDA Margin | 22.63% |
| EBIT Margin | 17.22% |
| FCF Margin | 23.51% |
Dividends & Yields
DexCom does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.89% |
| Shareholder Yield | 1.89% |
| Earnings Yield | 3.16% |
| FCF Yield | 4.66% |
Analyst Forecast
The average price target for DexCom is $88.20, which is 50.98% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $88.20 |
| Price Target Difference | 50.98% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 20 |
| Revenue Growth Forecast (5Y) | 13.83% |
| EPS Growth Forecast (5Y) | 26.06% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 13, 2022. It was a forward split with a ratio of 4:1.
| Last Split Date | Jun 13, 2022 |
| Split Type | Forward |
| Split Ratio | 4:1 |
Scores
DexCom has an Altman Z-Score of 5.5 and a Piotroski F-Score of 6.
| Altman Z-Score | 5.5 |
| Piotroski F-Score | 6 |